Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Japan Tobacco Inc.    2914   JP3726800000

JAPAN TOBACCO INC.

(2914)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Japan Tobacco : JT Receives Manufacturing and Marketing Approval of ENAROY® Tablets 2 mg・4 mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan

09/25/2020 | 02:05am EST

FOR IMMEDIATE RELEASE

Tokyo, September 25, 2020

JT Receives Manufacturing and Marketing Approval of

ENAROY® Tablets 2 mg4 mg

for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan

Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced that JT has today received manufacturing and marketing approval for ENAROY® Tablet 2 mg and 4 mg (generic name: enarodustat) (hereinafter "ENAROY®"), a hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for an indication of anemia associated with chronic kidney disease (CKD) in Japan.

ENAROY® is an orally-activeHIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism. The Phase 3 clinical studies confirmed the efficacy and safety of ENAROY® in anemic patients with CKD not on dialysis, on peritoneal dialysis and on hemodialysis.

JT and Torii expect ENAROY® to be a new option for the treatment of anemia associated with CKD in Japan. Under the terms of the October 2017 agreement between JT and Torii, the drug will exclusively be sold by Torii in Japan, following its inclusion in the National Health Insurance (NHI) price list. The drugs' launch date will be announced as soon as a decision is made.

Outline of approval

Product Name: ENAROY® Tablet 2 mg4 mg

Generic Name: Enarodustat

Indications: Anemia associated with CKD Dosage and Administration:

For patients with CKD not on dialysis and on peritoneal dialysis;

The recommended starting dose for adult patients is 2 mg taken orally once daily before a meal or at bedtime. Thereafter, the dose should be adjusted as appropriate depending on the patient's condition. The maximum dose is 8 mg per dose.

For patients with CKD on hemodialysis;

The recommended starting dose for adult patients is 4 mg taken orally once

daily before a meal or at bedtime. Thereafter, the dose should be adjusted as appropriate depending on the patient's condition. The maximum dose is 8 mg per dose.

ABOUT Anemia Associated with CKD

Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is considered to be a decreased ability to produce EPO in the kidney associated with renal dysfunction. Insufficient oxygen supply due to decreased erythrocyte counts associated with anemia decreases the energy production in organs and induces reduction in mobility and activities in daily life, which leads to a poor quality of life.

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 62,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under its Ploom brand, and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit

https://www.jt.com/.

Contact for Japan Tobacco Inc.:

Contact for Torii Pharmaceutical Co., Ltd.:

Dinesh Babu Thotakura, General Manager

Corporate Planning Department

Media and Investor Relations Division

(Public Relations)

Japan Tobacco Inc. Tokyo: +81-3-3582-3111

Torii Pharmaceutical Co., Ltd. Tokyo: +81-3-3231-6814

E-mail: jt.media.relations@jt.com

E-mail: webmaster@torii.co.jp

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Japan Tobacco Inc. published this content on 25 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 September 2020 06:04:07 UTC


© Publicnow 2020
All news about JAPAN TOBACCO INC.
11/19Big Tobacco gets a pandemic pick-me-up
RE
11/19JAPAN TOBACCO INC. : - Listing on the Japanese National Health Insurance Drug Pr..
AQ
11/18JAPAN TOBACCO : Listing on the Japanese National Health Insurance Drug Price Lis..
PU
11/02Nikkei rebounds from 2-month low on upbeat domestic earnings
RE
11/01Nikkei rebounds from 2-month low as earnings recover
RE
10/30JAPAN TOBACCO : 2020 Third Quarter Results
PU
10/30JAPAN TOBACCO INC. : Press Release
CO
10/30JAPAN TOBACCO INC. : 3rd quarter results
CO
10/27JAPAN TOBACCO INC. : quaterly earnings release
10/26JAPAN TOBACCO : Leaf Tobacco Deliberative Council Releases Its Report in Respons..
PU
More news
Financials
Sales 2020 2 089 B 20 030 M 20 030 M
Net income 2020 300 B 2 872 M 2 872 M
Net Debt 2020 573 B 5 496 M 5 496 M
P/E ratio 2020 12,8x
Yield 2020 7,08%
Capitalization 3 864 B 36 930 M 37 055 M
EV / Sales 2020 2,12x
EV / Sales 2021 2,04x
Nbr of Employees 61 975
Free-Float 55,1%
Chart JAPAN TOBACCO INC.
Duration : Period :
Japan Tobacco Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAPAN TOBACCO INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 2 363,53 JPY
Last Close Price 2 178,00 JPY
Spread / Highest target 42,3%
Spread / Average Target 8,52%
Spread / Lowest Target -17,4%
EPS Revisions
Managers
NameTitle
Masamichi Terabatake President, CEO & Representative Director
Yasutake Tango Chairman
Naohiro Minami CFO, Representative Director & Executive VP
Hiroyuki Miki Executive Officer, Head-Research & Development
Mutsuo Iwai Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
JAPAN TOBACCO INC.-10.46%36 692
ALTRIA GROUP, INC.-17.85%76 195
ITC LIMITED-17.73%32 505
PT HANJAYA MANDALA SAMPOERNA TBK-25.24%12 861
KT&G CORPORATION-8.21%9 614
PT GUDANG GARAM TBK-15.66%6 057